EP0672054A4 - A novel molecule which inhibits neuropeptide tyrosine biological function. - Google Patents

A novel molecule which inhibits neuropeptide tyrosine biological function.

Info

Publication number
EP0672054A4
EP0672054A4 EP93901575A EP93901575A EP0672054A4 EP 0672054 A4 EP0672054 A4 EP 0672054A4 EP 93901575 A EP93901575 A EP 93901575A EP 93901575 A EP93901575 A EP 93901575A EP 0672054 A4 EP0672054 A4 EP 0672054A4
Authority
EP
European Patent Office
Prior art keywords
biological function
novel molecule
neuropeptide tyrosine
inhibits
inhibits neuropeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93901575A
Other languages
German (de)
French (fr)
Other versions
EP0672054A1 (en
Inventor
Albert Tseng
Adam S Inglis
Lisa Selbie
Erica Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Prince of Wales Medical Research Institute Ltd POWMRI
Original Assignee
Garvan Institute of Medical Research
Prince of Wales Medical Research Institute Ltd POWMRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Institute of Medical Research, Prince of Wales Medical Research Institute Ltd POWMRI filed Critical Garvan Institute of Medical Research
Publication of EP0672054A1 publication Critical patent/EP0672054A1/en
Publication of EP0672054A4 publication Critical patent/EP0672054A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP93901575A 1991-12-19 1992-12-21 A novel molecule which inhibits neuropeptide tyrosine biological function. Withdrawn EP0672054A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPL010691 1991-12-19
AU106/91 1991-12-19
PCT/AU1992/000673 WO1993012139A1 (en) 1991-12-19 1992-12-21 A novel molecule which inhibits neuropeptide tyrosine biological function

Publications (2)

Publication Number Publication Date
EP0672054A1 EP0672054A1 (en) 1995-09-20
EP0672054A4 true EP0672054A4 (en) 1996-02-07

Family

ID=3775895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93901575A Withdrawn EP0672054A4 (en) 1991-12-19 1992-12-21 A novel molecule which inhibits neuropeptide tyrosine biological function.

Country Status (4)

Country Link
EP (1) EP0672054A4 (en)
JP (1) JPH08501055A (en)
CA (1) CA2126212A1 (en)
WO (1) WO1993012139A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
JP4106711B2 (en) * 1996-03-21 2008-06-25 萬有製薬株式会社 Aminopyridine derivatives
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
FR2754709B1 (en) 1996-10-23 1999-03-05 Sanofi Sa COSMETIC COMPOSITION CONTAINING AN ANTAGONIST OF GAMMA NEUROPEPTIDE RECEPTORS AND ALPHA 2 ANTAGONISTS THAT MAY BE INCORPORATED IN SUCH A COMPOSITION
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
DE602004026289D1 (en) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminyl INHIBITORS
US20050137142A1 (en) 2003-11-03 2005-06-23 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH490338A (en) * 1967-04-13 1970-05-15 Ciba Geigy Process for the production of ACTH-active peptides with extended action
EP0225020A2 (en) * 1985-10-19 1987-06-10 Beecham Group Plc Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of ViP
WO1991008223A1 (en) * 1989-12-01 1991-06-13 Basf Aktiengesellschaft Novel peptides derived from neuropeptide y
WO1993009227A1 (en) * 1991-11-06 1993-05-13 Garvan Institute Of Medical Research Human neuropeptide y-y1 receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
DE3811193A1 (en) * 1988-04-01 1989-10-19 Boehringer Ingelheim Kg Peptides, process for their preparation and pharmaceutical compositions containing these peptides
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists
EP0448765B1 (en) * 1990-03-30 1994-08-17 HEUMANN PHARMA GMBH & CO Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity
SE467340B (en) * 1990-07-04 1992-07-06 Perstorp Ab USE OF INOSITOL MONOPHOSPHATE FOR THE PREPARATION OF AN EFFECTIVE EFFECT AS A NEUROPEPTID Y (NPY) ANTAGONIST

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH490338A (en) * 1967-04-13 1970-05-15 Ciba Geigy Process for the production of ACTH-active peptides with extended action
EP0225020A2 (en) * 1985-10-19 1987-06-10 Beecham Group Plc Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of ViP
WO1991008223A1 (en) * 1989-12-01 1991-06-13 Basf Aktiengesellschaft Novel peptides derived from neuropeptide y
WO1993009227A1 (en) * 1991-11-06 1993-05-13 Garvan Institute Of Medical Research Human neuropeptide y-y1 receptor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALASUBRAMANIAN, A. ET AL.: "Synthseis and receptor affinities of partial sequences of peptide YY (PYY)", PEPTIDE RESEARCH, vol. 1, no. 1, pages 32 - 35, XP002039197 *
LACOMBE, J.M. ET AL.: "Malaria invasion of human erythrocytes", INT. J. PEPTIDE PROTEIN RES., vol. 32, pages 104 - 116, XP009038013 *
See also references of WO9312139A1 *
SERVIN, A.L. ET AL.: "Peptide-YY and Neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated ...", ENDOCRINOLOGY, vol. 124, no. 2, pages 692 - 700 *

Also Published As

Publication number Publication date
WO1993012139A1 (en) 1993-06-24
EP0672054A1 (en) 1995-09-20
CA2126212A1 (en) 1993-07-08
JPH08501055A (en) 1996-02-06

Similar Documents

Publication Publication Date Title
EP0672054A4 (en) A novel molecule which inhibits neuropeptide tyrosine biological function.
ZA926733B (en) 1,2-Dihydro-2-oxopyridines.
OA09816A (en) "Biological control agents".
ZA92908B (en) Compounds.
FI921125A0 (en) Ciclosporin.
AP9600796A0 (en) Novel insecticidal 2,4 diaminoquina-zolines
FI953489A (en) 2,6-diaminopuriinijohdannaisia
MX9201819A (en) BENZOHETEROCICLICOS COMPOUNDS.
MX9202978A (en) AMINO-4-ARYL-THIAZOLES COMPOUNDS.
EP0569493A4 (en) Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
ZA929517B (en) Compounds.
MX9204547A (en) NERISTATINE 1.
GB2260135B (en) Substituted 2,6-diaminotoluenes
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
FI912922A (en) ANALYZED FOER TILLTRAEDE I FLEXIBLA BEHAOLLARE.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
DE59202341D1 (en) SWASH PRESS.
ZA929724B (en) Ballisitc materials.
DE69205795D1 (en) Mesoprotheseunterlage.
DE69203865D1 (en) Thermo-transferdrucksystem.
DE69204801D1 (en) Hydroxy- oder oxosubstituierte alkylcyclopentene.
ZA929820B (en) Heisswinderschieber.
ZA929331B (en) Quinolylmethoxyphenyl-acetamides.
ZA925725B (en) Qinolin-2-yl-methoxybenzylhydroxyureas.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19951227

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960104